Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.
Melody effect: Wrong ‘Parle’ stock hits 5% upper circuit for 4th day, up 21% since PM Modi’s gift for Meloni
Parle Industries shares hit the 5% upper circuit for the fourth consecutive session amid speculation that investors are mistaking it for unlisted FMCG major Parle